Strengths and weaknesses of pneumococcal conjugate vaccines
Multivalent vaccines addressing an increasing number of Streptococcus pneumoniae types (7-, 10-, 13-, 15-, 20-valent) have been licensed over the last 22 years. The use of polysaccharide-protein conjugate vaccines has been pivotal in reducing the incidence of invasive pneumococcal disease despite th...
Gespeichert in:
| Veröffentlicht in: | Glycoconjugate journal 2023-04, Vol.40 (2), p.135-148 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 148 |
|---|---|
| container_issue | 2 |
| container_start_page | 135 |
| container_title | Glycoconjugate journal |
| container_volume | 40 |
| creator | Micoli, Francesca Romano, Maria Rosaria Carboni, Filippo Adamo, Roberto Berti, Francesco |
| description | Multivalent vaccines addressing an increasing number of
Streptococcus pneumoniae
types (7-, 10-, 13-, 15-, 20-valent) have been licensed over the last 22 years. The use of polysaccharide-protein conjugate vaccines has been pivotal in reducing the incidence of invasive pneumococcal disease despite the emergence of non-vaccine serotypes. Notwithstanding its undoubtable success, some weaknesses have called for continuous improvement of pneumococcal vaccination. For instance, despite their inclusion in pneumococcal conjugate vaccines, there are challenges associated with some serotypes. In particular,
Streptococcus pneumoniae
type 3 remains a major cause of invasive pneumococcal disease in several countries.
Here a deep revision of the strengths and weaknesses of the licensed pneumococcal conjugate vaccines and other vaccine candidates currently in clinical development is reported. |
| doi_str_mv | 10.1007/s10719-023-10100-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10027807</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2766721657</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-197953654da5e02e40d806d2b4ff9f0e6176eb60863253259a87f61e848a9f303</originalsourceid><addsrcrecordid>eNp9kU1PGzEQhi1UBCHwBzhUK_XSy5axvf5Y9VAh1FIkJA60Z8vxzoYNGzu1d1Px73EIBOihkqWRPM-88_ESckrhCwVQZ4mConUJjJcU8k_J98iECsXLqtbyA5kA06wE0HBIjlJaQC6qmD4gh1xKwUDQCfl6O0T08-EuFdY3xV-09x5TwlSEtlh5HJfBBedsX7jgF-PcDlisrXNdpo7Jfmv7hCfPcUp-__j-6-JneX1zeXVxfl26SomhpLWqBZeiaqxAYFhBo0E2bFa1bd0CSqokziRoyZnIr7ZatZKirrStWw58Sr5tdVfjbImNQz9E25tV7JY2PphgO_M-47s7Mw9rk2_ClAaVFT4_K8TwZ8Q0mGWXHPa99RjGZJiSUjEqxQb99A-6CGP0eb9MaS3yBavNSGxLuRhSitjupqGwaavM1hyTzTFP5hieiz6-3WNX8uJGBvgWSDnl5xhfe_9H9hEISpkp</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2788574240</pqid></control><display><type>article</type><title>Strengths and weaknesses of pneumococcal conjugate vaccines</title><source>MEDLINE</source><source>SpringerLink</source><creator>Micoli, Francesca ; Romano, Maria Rosaria ; Carboni, Filippo ; Adamo, Roberto ; Berti, Francesco</creator><creatorcontrib>Micoli, Francesca ; Romano, Maria Rosaria ; Carboni, Filippo ; Adamo, Roberto ; Berti, Francesco</creatorcontrib><description>Multivalent vaccines addressing an increasing number of
Streptococcus pneumoniae
types (7-, 10-, 13-, 15-, 20-valent) have been licensed over the last 22 years. The use of polysaccharide-protein conjugate vaccines has been pivotal in reducing the incidence of invasive pneumococcal disease despite the emergence of non-vaccine serotypes. Notwithstanding its undoubtable success, some weaknesses have called for continuous improvement of pneumococcal vaccination. For instance, despite their inclusion in pneumococcal conjugate vaccines, there are challenges associated with some serotypes. In particular,
Streptococcus pneumoniae
type 3 remains a major cause of invasive pneumococcal disease in several countries.
Here a deep revision of the strengths and weaknesses of the licensed pneumococcal conjugate vaccines and other vaccine candidates currently in clinical development is reported.</description><identifier>ISSN: 0282-0080</identifier><identifier>EISSN: 1573-4986</identifier><identifier>DOI: 10.1007/s10719-023-10100-3</identifier><identifier>PMID: 36652051</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antibodies, Bacterial ; Antigens ; Bacterial infections ; Biochemistry ; Biomedical and Life Sciences ; Drug resistance ; Ear diseases ; Epidemiology ; Humans ; Life Sciences ; Mini Review ; Pathology ; Penicillin ; Pneumococcal Infections - epidemiology ; Pneumococcal Infections - prevention & control ; Pneumococcal Vaccines - therapeutic use ; Pneumonia ; Polysaccharides ; Proteins ; Serotypes ; Streptococcus infections ; Streptococcus pneumoniae ; Vaccination ; Vaccines ; Vaccines, Conjugate - therapeutic use ; Virulence</subject><ispartof>Glycoconjugate journal, 2023-04, Vol.40 (2), p.135-148</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-197953654da5e02e40d806d2b4ff9f0e6176eb60863253259a87f61e848a9f303</citedby><cites>FETCH-LOGICAL-c475t-197953654da5e02e40d806d2b4ff9f0e6176eb60863253259a87f61e848a9f303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10719-023-10100-3$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10719-023-10100-3$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36652051$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Micoli, Francesca</creatorcontrib><creatorcontrib>Romano, Maria Rosaria</creatorcontrib><creatorcontrib>Carboni, Filippo</creatorcontrib><creatorcontrib>Adamo, Roberto</creatorcontrib><creatorcontrib>Berti, Francesco</creatorcontrib><title>Strengths and weaknesses of pneumococcal conjugate vaccines</title><title>Glycoconjugate journal</title><addtitle>Glycoconj J</addtitle><addtitle>Glycoconj J</addtitle><description>Multivalent vaccines addressing an increasing number of
Streptococcus pneumoniae
types (7-, 10-, 13-, 15-, 20-valent) have been licensed over the last 22 years. The use of polysaccharide-protein conjugate vaccines has been pivotal in reducing the incidence of invasive pneumococcal disease despite the emergence of non-vaccine serotypes. Notwithstanding its undoubtable success, some weaknesses have called for continuous improvement of pneumococcal vaccination. For instance, despite their inclusion in pneumococcal conjugate vaccines, there are challenges associated with some serotypes. In particular,
Streptococcus pneumoniae
type 3 remains a major cause of invasive pneumococcal disease in several countries.
Here a deep revision of the strengths and weaknesses of the licensed pneumococcal conjugate vaccines and other vaccine candidates currently in clinical development is reported.</description><subject>Antibodies, Bacterial</subject><subject>Antigens</subject><subject>Bacterial infections</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Drug resistance</subject><subject>Ear diseases</subject><subject>Epidemiology</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Mini Review</subject><subject>Pathology</subject><subject>Penicillin</subject><subject>Pneumococcal Infections - epidemiology</subject><subject>Pneumococcal Infections - prevention & control</subject><subject>Pneumococcal Vaccines - therapeutic use</subject><subject>Pneumonia</subject><subject>Polysaccharides</subject><subject>Proteins</subject><subject>Serotypes</subject><subject>Streptococcus infections</subject><subject>Streptococcus pneumoniae</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, Conjugate - therapeutic use</subject><subject>Virulence</subject><issn>0282-0080</issn><issn>1573-4986</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kU1PGzEQhi1UBCHwBzhUK_XSy5axvf5Y9VAh1FIkJA60Z8vxzoYNGzu1d1Px73EIBOihkqWRPM-88_ESckrhCwVQZ4mConUJjJcU8k_J98iECsXLqtbyA5kA06wE0HBIjlJaQC6qmD4gh1xKwUDQCfl6O0T08-EuFdY3xV-09x5TwlSEtlh5HJfBBedsX7jgF-PcDlisrXNdpo7Jfmv7hCfPcUp-__j-6-JneX1zeXVxfl26SomhpLWqBZeiaqxAYFhBo0E2bFa1bd0CSqokziRoyZnIr7ZatZKirrStWw58Sr5tdVfjbImNQz9E25tV7JY2PphgO_M-47s7Mw9rk2_ClAaVFT4_K8TwZ8Q0mGWXHPa99RjGZJiSUjEqxQb99A-6CGP0eb9MaS3yBavNSGxLuRhSitjupqGwaavM1hyTzTFP5hieiz6-3WNX8uJGBvgWSDnl5xhfe_9H9hEISpkp</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>Micoli, Francesca</creator><creator>Romano, Maria Rosaria</creator><creator>Carboni, Filippo</creator><creator>Adamo, Roberto</creator><creator>Berti, Francesco</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230401</creationdate><title>Strengths and weaknesses of pneumococcal conjugate vaccines</title><author>Micoli, Francesca ; Romano, Maria Rosaria ; Carboni, Filippo ; Adamo, Roberto ; Berti, Francesco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-197953654da5e02e40d806d2b4ff9f0e6176eb60863253259a87f61e848a9f303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies, Bacterial</topic><topic>Antigens</topic><topic>Bacterial infections</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Drug resistance</topic><topic>Ear diseases</topic><topic>Epidemiology</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Mini Review</topic><topic>Pathology</topic><topic>Penicillin</topic><topic>Pneumococcal Infections - epidemiology</topic><topic>Pneumococcal Infections - prevention & control</topic><topic>Pneumococcal Vaccines - therapeutic use</topic><topic>Pneumonia</topic><topic>Polysaccharides</topic><topic>Proteins</topic><topic>Serotypes</topic><topic>Streptococcus infections</topic><topic>Streptococcus pneumoniae</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, Conjugate - therapeutic use</topic><topic>Virulence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Micoli, Francesca</creatorcontrib><creatorcontrib>Romano, Maria Rosaria</creatorcontrib><creatorcontrib>Carboni, Filippo</creatorcontrib><creatorcontrib>Adamo, Roberto</creatorcontrib><creatorcontrib>Berti, Francesco</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Glycoconjugate journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Micoli, Francesca</au><au>Romano, Maria Rosaria</au><au>Carboni, Filippo</au><au>Adamo, Roberto</au><au>Berti, Francesco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Strengths and weaknesses of pneumococcal conjugate vaccines</atitle><jtitle>Glycoconjugate journal</jtitle><stitle>Glycoconj J</stitle><addtitle>Glycoconj J</addtitle><date>2023-04-01</date><risdate>2023</risdate><volume>40</volume><issue>2</issue><spage>135</spage><epage>148</epage><pages>135-148</pages><issn>0282-0080</issn><eissn>1573-4986</eissn><abstract>Multivalent vaccines addressing an increasing number of
Streptococcus pneumoniae
types (7-, 10-, 13-, 15-, 20-valent) have been licensed over the last 22 years. The use of polysaccharide-protein conjugate vaccines has been pivotal in reducing the incidence of invasive pneumococcal disease despite the emergence of non-vaccine serotypes. Notwithstanding its undoubtable success, some weaknesses have called for continuous improvement of pneumococcal vaccination. For instance, despite their inclusion in pneumococcal conjugate vaccines, there are challenges associated with some serotypes. In particular,
Streptococcus pneumoniae
type 3 remains a major cause of invasive pneumococcal disease in several countries.
Here a deep revision of the strengths and weaknesses of the licensed pneumococcal conjugate vaccines and other vaccine candidates currently in clinical development is reported.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>36652051</pmid><doi>10.1007/s10719-023-10100-3</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0282-0080 |
| ispartof | Glycoconjugate journal, 2023-04, Vol.40 (2), p.135-148 |
| issn | 0282-0080 1573-4986 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10027807 |
| source | MEDLINE; SpringerLink |
| subjects | Antibodies, Bacterial Antigens Bacterial infections Biochemistry Biomedical and Life Sciences Drug resistance Ear diseases Epidemiology Humans Life Sciences Mini Review Pathology Penicillin Pneumococcal Infections - epidemiology Pneumococcal Infections - prevention & control Pneumococcal Vaccines - therapeutic use Pneumonia Polysaccharides Proteins Serotypes Streptococcus infections Streptococcus pneumoniae Vaccination Vaccines Vaccines, Conjugate - therapeutic use Virulence |
| title | Strengths and weaknesses of pneumococcal conjugate vaccines |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T14%3A10%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Strengths%20and%20weaknesses%20of%20pneumococcal%20conjugate%20vaccines&rft.jtitle=Glycoconjugate%20journal&rft.au=Micoli,%20Francesca&rft.date=2023-04-01&rft.volume=40&rft.issue=2&rft.spage=135&rft.epage=148&rft.pages=135-148&rft.issn=0282-0080&rft.eissn=1573-4986&rft_id=info:doi/10.1007/s10719-023-10100-3&rft_dat=%3Cproquest_pubme%3E2766721657%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2788574240&rft_id=info:pmid/36652051&rfr_iscdi=true |